Explore pages for life sciences sub-sectors on this website: Biotechnology & pharmaceuticals

UK biotechnology & pharmaceuticals opportunities The UK is one of the world’s most attractive locations for international pharmaceutical and biotechnology operations.

UK companies account for 40 per cent of biotechnology products in the pipeline by European public companies.

Moreover, 45 per cent of new biotechnology drugs in late-stage clinical trials (Phase III) in Europe are from the UK.

The UK is also the world’s number-two pharmaceuticals exporter and, with R&D investment of over £3.3 billion in 2005, it ranks with the USA and Japan as one of the top three centres for pharmaceutical research.

To read our Inward Investment Report 2008/9 in Life Sciences, click here.

Find the top 10 reasons for undertaking clinical research and trials in the UK.

Get information on developing regenerative medicines in the UK.

Or read case studies for international biotech & pharma companies that are already doing business in the UK.

英国公司研制的生物技术产品占欧洲上市公司产品总数的40%。

此外，欧洲新的生物技术药品后期临床实验（第三期实验）有45%是在英国进行的。

英国还是世界第二大药品出口国，2005年的研发投资超过33亿英镑，与美国和日本并列为世界三大药品研制中心。

请阅读我们的英国生物科学资料册，了解更多英国生物与新药研究方面的重要资讯。

了解在英国进行临床研究与临床实验的10个重要理由。

获得关于在英国开发再生性医疗技术方面的信息。

阅读案例分析，了解已有哪些国际生物技术和制药公司在英国投资运作。

View a three minute video showcasing the UK’s expertise in Biotechnology and Pharmaceuticals.

Showcasing the UK Biotechnology and Pharmaceutical Industry

Dr Alan Smith, chief scientific officer of leading biotechnology firm Genzyme, talks about why the UK market is so important to the biosciences sector and how UKTI has supported its ongoing development.

Genzyme – video case study